Richter stands by projection for flat revenue in 2012

Pharma

Hungarian drugmaker Gedeon Richter is standing by its projection for stagnating revenue this year, CEO Erik Bogsch said at a press conference on Thursday, after the company published its H1 earnings report.

Turnover in Hungary could drop 15-20% for the year, calculated in forints, but more than 20% in euro, Bogsch said. First-half domestic sales were down 10.8% in forints and fell 18.7% in euro, the report shows. Bogsch attributed the slide to changes to market regulation and falling prices. He noted that fiscal tightening was being felt in the healthcare sectors and in the area of drug subsidies in all countries, and the process of getting new drugs approved for support by social insurance had become slower and more difficult. Bogsch said markets in the CIS and in the European Union were the engine of growth in Richter's first half. The launch of sales of the drug Esmya in some European countries also supported the increase, he added. Sales in the CIS accounted for 44% of Richter's revenue during the period.

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.

Support the BBJ

Industry